Effects of tamoxifen in patients with myeloproliferatIve disorders
| ISRCTN | ISRCTN65011803 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN65011803 |
| EudraCT/CTIS number | 2015-005497-38 |
| Secondary identifying numbers | 30849 |
- Submission date
- 13/06/2016
- Registration date
- 20/06/2016
- Last edited
- 29/10/2024
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Cancer
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Plain English Summary
Contact information
Mrs Sonia Fox
Public
Public
Cancer Research UK Clinical Trials Unit
Centre for Clinical Haematology
Queen Elizabeth Hospital
Edgbaston
Birmingham
B15 2TH
United Kingdom
Study information
| Study design | Non-randomised; Interventional; Design type: Treatment, Drug |
|---|---|
| Primary study design | Interventional |
| Secondary study design | Non randomised study |
| Study setting(s) | Hospital |
| Study type | Treatment |
| Participant information sheet | Not available in web format, please use the contact details below to request a patient information sheet |
| Scientific title | Effects of TAMoxifen on the Mutant Allele Burden and Disease Course in Patients with MyeloprolifeRatIve Neoplasms |
| Study acronym | TAMARIN |
| Study hypothesis | The aim of this study is to assess whether giving tamoxifen to patients receiving therapy for their MPN reduces the number of mutated cells found in the blood by ≥50% after 24 weeks of treatment compared to the start of the study. |
| Ethics approval(s) | East Midlands – Derby Research Ethics Committee, 24/05/2016, ref: 16/EM/0181 |
| Condition | MyeloproliferatIve neoplasms |
| Intervention | Patients who consent to participate in the study will need to attend hospital at baseline to receive a medical exam (including palpation of the liver and spleen), blood tests (including a full fasting lipid profile), an abdominal ultrasound if they have PV or ET and a blood sample taken for central review at Cambridge Blood and Stem Cell Biobank to ensure that they are eligible for the trial and that it is safe for them to enter the trial. Patients will also be asked to complete a short Quality of Life questionnaire which has been developed specifically for patients with MPNs. Once registered to the study, patients will have a minimum of 24 weeks of treatment with tamoxifen at 20mg od as an oral tablet. Patients will be seen 2 weeks after starting treatment for blood tests and a medical exam and then again at weeks 4, 8, 12, 18 and 24. At weeks 12 and 24 they will also have a blood sample taken for central review at Cambridge and a full fasting lipid profile. At week 24, the patient will also be asked to have a bone marrow aspirate and trephine biopsy and complete the same Quality of Life Questionnaire they completed at baseline. If the patient had an enlarged spleen on the baseline ultrasound, an ultrasound may be repeated at any point during the 24 weeks if the blood counts suggest the patient is in Complete Response. If the patient continues trial therapy beyond 24 weeks, they will be seen a minimum of 12 weekly for blood tests and a medical exam. Patients will also be required to attend their local hospital 28 days after the final dose of tamoxifen for blood tests and a medical exam. |
| Intervention type | Drug |
| Pharmaceutical study type(s) | |
| Phase | Not Applicable |
| Drug / device / biological / vaccine name(s) | Tamoxifen |
| Primary outcome measure | Primary outcome measures as of 19/11/2018: Reduction in the peripheral blood JAK2V617F, CALR 5bp insertion (exon 9) or CALR 52bp deletion (exon 9) mutant allele burden of ≥50% at 24 weeks measured using validated assays for JAK2 and CALR. Primary outcomes as of 27/06/2017: Reduction in the peripheral blood JAK2V617F, CALR 5bp insertion (exon 9) or CALR 52bp deletion (exon 9) mutant allele burden of ≥50% is measured using validated assays for JAK2 and CALR respectively at baseline and 24 weeks. Previous primary outcomes: Peripheral blood JAK2V617F or CALR mutant allele burden is measured using validated assays for JAK2V617F and CALR respectively at baseline and 24 weeks. |
| Secondary outcome measures | Secondary outcome measures as of 19/11/2018: 1. Proportion of patients with a reduction in the peripheral blood JAK2-V617F, CALR 5bp insertion (exon 9), or CALR 52bp deletion (exon 9) mutant allele burden of ≥50% at 12 weeks 2. Toxicity measured as the number of grade 3 and 4 adverse events reported. 3. The number of thrombotic events of any grade reported and validated. 4. Duration of haematological response calculated as time from registration to progression for patients who enter the study in response (CR or PR). For patients who enter the trial in stable disease, the time between first recorded response to the date of progression. Progression is defined as loss of response for PV/ET patients and evidence of disease progression for MF patients. PV/ET patients who continue to achieve a response, or MF patients who have no evidence of disease progression at the end of the trial will be censored at date last seen. Haematological response is defined according to 2009 ELN criteria for ET/PV patients [1] and no evidence of disease progression for MF patients according to IWG-MRT response criteria [2] (for criteria see Appendices 5 & 6) 5. Proportion of patients in each response category according to IWG-MRT response criteria [2] for MF patients and 2013 ELN response criteria [3] for ET/PV patients at 24 weeks of treatment 6. Proportion of patients showing an improvement in response category at 24 weeks compared to baseline according to 2009 ELN criteria for ET/PV patients [1] and according to IWG-MRT response criteria [2] for MF patients. Patients who are in a higher category at week 24 compared to baseline will be classed a success. Patients who enter the trial in CR and who maintain a CR will also be classed as a success in this outcome Exploratory Outcome Measures: 1. Change in allele burden between weeks 12, 24 and baseline. 2. Proportion of patients showing a decrease in requirement for cytoreduction at 24 weeks compared to baseline 3. Proportion of patients showing a decrease in allele burden of ≥50% at 36 and 48 weeks compared to baseline 4. Duration of reduction in the mutant allele burden, defined as time from first observed reduction of ≥50% until reduction from baseline becomes <25% or patients death. 5. Expression (RNAseq), DNA-protein interaction (ChipSeq) and methylation studies focused on oestrogen receptor signalling in haematopoietic progenitors obtained from peripheral blood and bone marrow before (peripheral blood only) and after tamoxifen treatment Secondary outcome measures as of 27/06/2017: 1. Proportion of patients with a reduction in the peripheral blood JAK2-V617F, CALR 5bp insertion (exon 9), or CALR 52bp deletion (exon 9) mutant allele burden of ≥50% is measured using validated assays for JAK2 and CALR respectively at baseline and 12 weeks 2. Toxicity measured as the number of grade 3 and 4 adverse events reported according to CTCAE for the duration of treatment and including 4 weeks after the last administration of trial treatment. 3. The number of thrombotic events of any grade reported and validated, according to CTCAE for the duration of treatment and including 4 weeks after the last administration of trial treatment 4. Duration of haematological response will be assessed by the local investigator at baseline and after two, four, eight, 12, 18 and 24 weeks of treatment according to 2009 ELN criteria for ET/PV patients and to IWG-MRT response criteria for MF patients 5. Proportion of patients in each response category according to IWG-MRT response criteria for MF patients and 2013 ELN response criteria for ET/PV patients is assessed by the local investigator after 24 weeks of treatment 6. Proportion of patients showing an improvement in response category at 24 weeks compared to baseline according to 2009 ELN criteria for ET/PV patients and according to IWG-MRT response criteria for MF patients is assessed by the local investigator after 24 weeks of treatment compared to baseline Exploratory outcome measures: 1. Proportion of patients showing a decrease in JAK2-V617F, CALR 5bp insertion (exon 9), or CALR 52bp deletion (exon 9) allele burden is measured using validated assays for JAK2 and CALR respectively at baseline and 12 weeks 2. Proportion of patients showing a decrease in JAK2-V617F, CALR 5bp insertion (exon 9), or CALR 52bp deletion (exon 9) allele burden is measured using validated assays for JAK2 and CALR respectively at baseline and 24 weeks 3. Proportion of patients showing a decrease in requirement for cytoreduction as reported by the local investigator at baseline and 24 weeks 4. The expression (RNAseq), DNA-protein interaction (CHIP-Seq) and methylation studies focused on oestrogen receptor signalling in haematopoietic progenitors will be performed in the lab of Dr Mendez-Ferrer at the University of Cambridge following the collection of peripheral blood (baseline and 24 weeks) and bone marrow aspirate samples (24 weeks only) Previous secondary outcome measures: 1. Peripheral blood JAK2V617F or CALR mutant allele burden is measured using validated assays for JAK2V617F and CALR respectively at baseline and 12 weeks 2. Peripheral blood JAK2V617F or CALR mutant allele burden is measured using validated assays for JAK2V617F and CALR respectively at baseline and 24 weeks 3. Peripheral blood JAK2V617F or CALR mutant allele burden is measured using validated assays for JAK2V617F and CALR respectively at baseline and 12 weeks 4. Toxicity measured as the number of grade 3 and 4 adverse events reported according to CTCAE for the duration of treatment (and including 4 weeks after the last administration of trial treatment). 5. Thrombotic events of any grade reported according to CTCAE for the duration of treatment (and including 4 weeks after the last administration of trial treatment) 6. Duration of haematological response calculated as time from registration to loss of response for PV/ET patients or evidence of disease progression for MF patients. PV/ET patients who continue to achieve a response, or MF patients who have no evidence of disease progression at the end of the trial will be censored at date last seen 7. Response according to IWG-MRT response criteria for MF and 2013 ELN response for ET/PV measured at 24 weeks |
| Overall study start date | 25/11/2015 |
| Overall study end date | 17/02/2021 |
Eligibility
| Participant type(s) | Patient |
|---|---|
| Age group | Adult |
| Sex | Both |
| Target number of participants | Planned Sample Size: 42; UK Sample Size: 42 |
| Total final enrolment | 38 |
| Participant inclusion criteria | Current inclusion criteria as of 27/06/2017: 1. Age ≥ 60 years (men aged between 50-59 may also be considered following discussion with the Chief Investigator) 2. Women must be post-menopausal (defined as amenorrhoeic for at least 12 consecutive months following cessation of all exogenous hormonal treatments) 3. Confirmed diagnosis of JAK2-V617F,CALR 5bp insertion (exon 9) or CALR 52bp deletion (exon 9) positive Essential Thrombocythaemia (ET), Polycythaemia Vera (PV) or Myelofibrosis (MF) (primary or secondary) for ≥ 6 months 4. JAK2-V617F, CALR 5bp insertion (exon 9) or CALR 52bp deletion (exon 9) mutant allele burden ≥ 20% in peripheral blood granulocyte DNA at study entry (assessed via central review) 5. WHO performance status 0-2 6. For patients with PV or ET, maintenance of platelet count ≤600 x 109/L, WBC ≤25 x 109/L and venesection requirements ≤1 per month for the previous 3 months prior to registration, without introduction of any new therapeutic agents for their MPN for 6 months prior to registration 7. For patients with MF, there must not have been any evidence of disease progression* for the previous 6 months (prior to registration) and no new therapeutic agents for their MPN introduced during this period 8. Patients receiving cytoreductive therapy (with the exception of interferon alpha or investigational agents) for their MPN (not solely aspirin or venesection) 9. Adequate hepatic function, defined as: 9.1. bilirubin ≤ 1.5 x ULN (patients with elevated bilirubin due to Gilbert’s syndrome are eligible) 9.2.AST/ALT/ALP ≤ 2.5 x ULN 10. Adequate renal function (creatinine clearance >30 mL/min) 11. Male patients must agree to use effective contraception during participation in the trial and for 2 months after the last dose of trial treatment 12. Patient must be able to give written informed consent *Defined by IWG-MRT ELN criteria. Please note no baseline bone marrow is required to confirm absence of “Leukemic transformation confirmed by a bone marrow blast count of ≥20%”. Previous inclusion criteria: 1. Age ≥ 60 years (men aged between 50-59 may also be considered following discussion with the Chief Investigator) 2. Women must be post-menopausal (defined as amenorrhoeic for at least 12 consecutive months following cessation of all exogenous hormonal treatments) 3. Confirmed diagnosis of JAK2-V617F or CALR positive Essential Thrombocythaemia (ET), Polycythaemia Vera (PV) or Myelofibrosis (MF) (primary or secondary) for ≥ 6 months 4. JAK2-V617F or CALR mutant allele burden ≥ 20% in peripheral blood granulocyte DNA at study entry (assessed via central review) 5. WHO performance status 0-2 6. For patients with PV or ET, maintenance of at least a partial haematological response according to 2009 ELN criteria must have been achieved for the previous 6 months (prior to registration), without introduction of any new therapeutic agents for their MPN 7. For patients with MF, there must not have been any evidence of disease progression* for the previous 6 months (prior to registration) and no new therapeutic agents for their MPN introduced during this period. 8. Patients receiving cytoreductive therapy for their MPN (not solely aspirin or venesection) 9. Adequate hepatic function, defined as: 9.1. bilirubin ≤ 1.5 x upper limit of normal (ULN) (patients with elevated bilirubin due to Gilbert’s syndrome are eligible) 9.2. AST/ALT/ALP ≤ 2.5 x ULN 10. Adequate renal function (creatinine clearance > 30 mL/min) 11. Male patients must agree to use effective contraception during participation in the trial and for 2 months after the last dose of trial treatment 12. Patient must be able to give written informed consent *Defined by IWG-MRT ELN criteria (Appendix 6). Please note no baseline bone marrow is required to confirm absence of “Leukemic transformation confirmed by a bone marrow blast count of ≥ 20%” |
| Participant exclusion criteria | Current exclusion criteria as of 27/06/2017: 1. Leukaemic transformation (>20% blasts in blood, marrow or extramedullary site). 2. Accelerated phase of disease as indicated by ≥10% blasts in the peripheral blood 3. Treatment of ET, PV or MF with Interferon alpha or other investigational agents for their MPN within 6 months prior to trial entry. JAK inhibitors, such as ruxolitinib, are allowed if taken continuously for ≥6 months prior to registration (dose changes during that period will be allowed) 4. Any of the following previous thrombotic events at any time: 4.1. Portal or other splanchnic venous thrombosis 4.2. Vascular access complication 4.3. Ischemia cerebrovascular 4.4. Stroke 4.5. Transient Ischaemic attack 4.6. Superficial thrombophlebitis 4.7. Venous Thromboembolic events including pulmonary embolism (PE) and deep vein thrombosis (DVT) 4.8. Peripheral vascular ischemia 4.9. Visceral arterial ischemia 4.10. Acute coronary syndrome 4.11. Myocardial infarction 5. Previous malignancy within 5 years with the exception of adequately treated cervical carcinoma in situ or localized non-melanoma skin cancer 6. Previous endometrial cancer, hyperplasia or polyps 7. Prior treatment with hematopoietic stem cell transplantation 8. Patients who do not carry JAK-2V617F, CALR 5bp insertion (exon 9) or CALR 52bp deletion (exon 9) mutations, or whose allele burden is <20% at study entry (assessed via central review) 9. Female patients receiving hormone replacement therapy 10. Hypertriglyceridemia > grade 1 11. Any serious underlying medical condition (at the judgment of the Investigator), which could impair the ability of the patient to participate in the trial (e.g. liver disease, active autoimmune disease, uncontrolled diabetes, uncontrolled infection (HIV, Hepatitis B and C), known genetic defect (apart from MPN) relating to venous thromboembolic events, or psychiatric disorder precluding understanding of trial information) 12. Known hypersensitivity to tamoxifen or hypersensitivity to any other component of tamoxifen 13. Concomitant drugs contraindicated for use with the trial drug according to the Summary of Product Characteristics (Appendix 8) 14. Known planned scheduled elective surgery during study with the exception of dental and low risk eye surgery (e.g. cataracts) Previous exclusion criteria: 1. Leukaemic transformation ( > 20% blasts in blood, marrow or extramedullary site). 2. Accelerated phase of disease as indicated by > 5% blasts in the peripheral blood 3. Treatment of ET, PV or MF with Interferon alpha or JAK inhibitors, such as ruxolitinib, or other investigational agents for their MPN within 6 months prior to trial entry 4. Any of the following previous thrombotic events at any time: 4.1. Portal or other splanchnic venous thrombosis 4.2. Vascular access complication 4.3. Ischemia cerebrovascular 4.4. Stroke 4.5. Transient Ischaemic attack 4.6. Superficial thrombophlebitis 4.7. Venous Thromboembolic events including pulmonary embolism (PE) and deep vein thrombosis (DVT) 4.8. Peripheral vascular ischemia 4.9. Visceral arterial ischemia 4.10. Acute coronary syndrome 4.11. Myocardial infarction 5. Previous malignancy within 5 years with the exception of adequately treated cervical carcinoma in situ or localized non-melanoma skin cancer 6. Previous endometrial cancer, hyperplasia or polyps 7. Prior treatment with hematopoietic stem cell transplantation 8. Patients who do not carry any mutations in JAK2V617F or CALR or allele burden < 20% 9. Female patients receiving hormone replacement therapy 10. Hypertriglyceridemia > grade 1 11. Any serious underlying medical condition (at the judgment of the Investigator), which could impair the ability of the patient to participate in the trial (e.g. liver disease, active autoimmune disease, uncontrolled diabetes, uncontrolled infection (HIV, Hepatitis B and C), known genetic defect (apart from MPN) relating to venous thromboembolic events, or psychiatric disorder precluding understanding of trial information) 12. Known hypersensitivity to tamoxifen or hypersensitivity to any other component of tamoxifen 13. Concomitant drugs contraindicated for use with the trial drug according to the Summary of Product Characteristics 14. Known planned scheduled elective surgery during study with the exception of dental and low risk eye surgery (e.g. cataracts) |
| Recruitment start date | 01/08/2016 |
| Recruitment end date | 20/06/2019 |
Locations
Countries of recruitment
- England
- Northern Ireland
- Scotland
- United Kingdom
- Wales
Study participating centres
Addenbrooke’s Hospital
Hills Road
Cambridge
CB2 0QQ
United Kingdom
Cambridge
CB2 0QQ
United Kingdom
Beatson West of Scotland Cancer Centre
1053 Great Western Road
Glasgow
G12 0YN
United Kingdom
Glasgow
G12 0YN
United Kingdom
Belfast City Hospital
Lisburn Road
Belfast
BT9 7AB
United Kingdom
Belfast
BT9 7AB
United Kingdom
Birmingham Heartlands Hospital
Bordesley Green East
Birmingham
B9 5SS
United Kingdom
Birmingham
B9 5SS
United Kingdom
Churchill Hospital
Old Road
Oxford
OX3 7LJ
United Kingdom
Oxford
OX3 7LJ
United Kingdom
Clatterbridge Cancer Centre
Clatterbridge Road Site
Wirral
CH63 4JY
United Kingdom
Wirral
CH63 4JY
United Kingdom
Good Hope Hospital
Rectory Road
Sutton Coldfield
B75 7RR
United Kingdom
Sutton Coldfield
B75 7RR
United Kingdom
Guy’s Hospital
Great Maze Pond
London
SE1 9RT
United Kingdom
London
SE1 9RT
United Kingdom
Hammersmith Hospital
Du Cane Road
London
W12 0HS
United Kingdom
London
W12 0HS
United Kingdom
Nottingham City Hospital
City Hospital Campus
Nottingham
NG5 1PB
United Kingdom
Nottingham
NG5 1PB
United Kingdom
Royal Devon and Exeter Hospital
Barrack Road
Exeter
EX2 5DW
United Kingdom
Exeter
EX2 5DW
United Kingdom
Royal Hallamshire Hospital
Glossop Road
Sheffield
S10 2JF
United Kingdom
Sheffield
S10 2JF
United Kingdom
Royal Stoke University Hospital
Newcastle Road
Stoke-on-Trent
ST4 6QG
United Kingdom
Stoke-on-Trent
ST4 6QG
United Kingdom
Southampton General Hospital
Tremona Road
Southampton
SO16 6YD
United Kingdom
Southampton
SO16 6YD
United Kingdom
St James’s University Hospital
Beckett Street
Leeds
LS9 7TF
United Kingdom
Leeds
LS9 7TF
United Kingdom
The Queen Elizabeth Hospital
Edgbaston
Birmingham
B15 2TH
United Kingdom
Birmingham
B15 2TH
United Kingdom
University College London Hospital
235 Euston Road
London
NW1 2BU
United Kingdom
London
NW1 2BU
United Kingdom
University Hospital of Wales
Heath Park
Cardiff
CF14 4XW
United Kingdom
Cardiff
CF14 4XW
United Kingdom
Sponsor information
University of Birmingham
Hospital/treatment centre
Hospital/treatment centre
Edgbaston
Birmingham
B15 2TT
England
United Kingdom
"ROR" |
https://ror.org/03angcq70 |
|---|
Funders
Funder type
Charity
Bloodwise TAP
No information available
Results and Publications
| Intention to publish date | 20/02/2022 |
|---|---|
| Individual participant data (IPD) Intention to share | No |
| IPD sharing plan summary | Data sharing statement to be made available at a later date |
| Publication and dissemination plan | Results of this trial will be submitted for publication in a peer-reviewed journal. |
| IPD sharing plan | The data sharing plans for the current study are unknown and will be made available at a later date. |
Study outputs
| Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
|---|---|---|---|---|---|
| Protocol file | version 4.0 | 29/10/2018 | 31/01/2023 | No | No |
| Abstract results | Presented at ASH | 05/11/2020 | 15/02/2023 | No | No |
| Basic results | 15/02/2023 | 15/02/2023 | No | No | |
| HRA research summary | 28/06/2023 | No | No | ||
| Results article | 25/11/2023 | 08/08/2024 | Yes | No |
Additional files
Editorial Notes
29/10/2024: Internal review.
08/08/2024: Publication reference added.
15/02/2023: The following changes have been made:
1. An updated basic results summary has been uploaded.
2. Abstract reference added.
14/02/2023: The basic results summary has been removed, pending addition of an updated version.
31/01/2023: Uploaded protocol (not peer-reviewed) as an additional file.
15/02/2022: The basic results have been uploaded as an additional file.
18/01/2022: The overall end date was changed from 31/12/2020 to 17/02/2021.
10/01/2022: The intention to publish date has been changed from 20/06/2021 to 20/02/2022.
18/05/2020: The following changes were made to the trial record:
1. The overall trial end date was changed from 30/04/2020 to 31/12/2020.
2. The intention to publish date was changed from 28/08/2020 to 20/06/2021.
03/07/2019: The total final enrolment was added.
02/07/2019: The recruitment end date was changed from 30/06/2019 to 20/06/2019.
21/05/2019: The recruitment end date was changed from 30/04/2019 to 30/06/2019.
02/04/2019: The condition has been changed from "Specialty: Cancer, Primary sub-specialty: Haematological oncology; UKCRC code/ Disease: Cancer/ Malignant neoplasms, stated or presumed to be primary, of lymphoid, haematopoietic and related tissue" to "MyeloproliferatIve neoplasms" following a request from the NIHR.
15/01/2019: The following changes have been made to the trial record:
1. The recruitment end date has been changed from 31/12/2018 to 30/04/2019.
2. The overall trial end date has been changed from 31/12/2019 to 30/04/2020.
3. The intention to publish date has been changed from 28/04/2020 to 28/08/2020.
19/11/2018: The following changes were made:
1. The contact details were updated.
2. The primary outcome measures were updated.
3. The secondary outcome measures were updated.
4. The overall trial end date was changed from 31/07/2018 to 31/12/2019.
5. The recruitment end date was changed from 31/07/2017 to 31/12/2018.
6. The trial participating centres were updated.
7. The intention to publish date was changed from 01/05/2018 to 28/04/2020.
8. The participant level data was updated.
9. The IPD sharing statement was updated.
27/06/2017: Updated primary and secondary outcome measures. Funder name changed from Leukaemia and Lymphoma Research to Bloodwise. Updated inclusion and exclusion criteria.
22/09/2016: Cancer Help lay summary added.
